Biotechnology

GT Biopharma

GT Biopharma Announces Shift Toward Precision Medicine in Oncology Industry

GT Biopharma's 1st Phase Clinical Trial for Blood Cancers Shows Promising Results

Jonathan Aschoff Maintains Buy Rating on GT Biopharma

GT Biopharma released FY2025 9 Months earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -1.7053

GT Biopharma released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8267 (forecast USD -0.38)

GT Biopharma completes first phase trial for cancer drug

GT Biopharma released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.55 (forecast USD -0.68)

GT Biopharma released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -0.8962

GT Biopharma Modifies Share Purchase Agreement, Changes Board Members

GT Biopharma's GTB-3650 Trial Advances in Blood Cancer Treatment

GT Biopharma Inc reports improved Q1 EPS loss

GT Biopharma released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3309 (forecast USD -0.64)

GT Biopharma Inc Expected to Report a Loss of 64 Cents Per Share

GT Biopharma Inc reports Q1 2025 loss forecast and maintains buy rating

GT Biopharma released FY2024 Annual Earnings on February 21 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -6.9369 USD (forecast -6.79 USD)

GT Biopharma released FY2024 Q4 earnings on February 21 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.6721 USD (forecast -1.55 USD)

GT Biopharma Administers First Dose of GTB-3650

GT Biopharma released FY2024 Q3 earnings on November 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.5266 USD (forecast -2.7 USD)

GT Biopharma released FY2024 Cumulative 3Q Earnings on November 14, 2024 (EST), with Revenue at 0 and EPS at -5.335

GT Biopharma's GTB-3650 Receives FDA Approval for Clinical Trials

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap